Methylphenidate transdermal system: A multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 12, Issue 6, 2010, Pages

  Warshaw, Erin M ^a   Squires, Liza ^b   Li, Yunfeng ^b   Civil, Richard ^b   Paller, Amy S ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b SHIRE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

AGGRESSION; ANOREXIA; APPLICATION SITE BURNING; APPLICATION SITE DISCOMFORT; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTACT DERMATITIS; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SENSITIZATION; DRUG WITHDRAWAL; DYSPHORIA; EDEMA; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MENTAL INSTABILITY; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATCH TEST; POLLAKISURIA; POLYDIPSIA; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; SYSTOLIC BLOOD PRESSURE; TIC; UPPER ABDOMINAL PAIN; URTICARIA; WEIGHT REDUCTION;

EID: 79251475546     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.10m00996pur     Document Type: Article

References (29)

1. Bloom B, Dey AN, Freeman G. Summary health statistics for US children: National Health Interview Survey, 2005. Vital Health Stat 10. 2006;231(231):1-84.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
3. Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1996;35(3):343-351.
4. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
5. Bush G, Spencer TJ, Holmes J, et al. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task. Arch Gen Psychiatry. 2008;65(1):102-114.
6. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(suppl 2):S46-S53.
7. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs. 2003;5(12):833-841.
8. Wilens TE, Boellner SW, López FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(6):700-708.
9. McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006;9(3):476-485.
10. Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(1):149-159.
11. Musel AL, Warshaw EM. Cutaneous reactions to transdermal therapeutic systems. Dermatitis. 2006;17(3):109-122.
12. Pelham WE Jr, Manos MJ, Ezzell CE, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(6):522-529.
13. Pelham WE, Burrows-Maclean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol. 2005;13(2):111-126.
14. Findling RL, Wigal SB, Bukstein OG, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther. 2009;31(8):1844-1855.
15. Arnold LE, Bozzolo DR, Hodgkins P, et al. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr Med Res Opin. 2010;26(1):129-137.
16. Daytrana [package insert]. Wayne, PA: Shire US Inc; 2008.
17. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: The Guilford Press; 1998.
18. Fowler JF, Warshaw EM, Squires L. Methylphenidate patch-test protocol and irritancy threshold determination in healthy adult subjects. Dermatitis. 2009;20(5):271-274.
19. Pratt MD, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch-test results, 2001-2002 study period. Dermatitis. 2004;15(4):176-183.
20. National Institute of Mental Health. CGI (Clinical Global Impressions) scale. Psychopharmacol Bull. 1985;21:839-843.
21. Warshaw EM, Paller AS, Fowler JF, et al. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Clin Ther. 2008;30(2):326-337.
22. Horning JR, Zawada ET Jr, Simmons JL, et al. Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension. Chest. 1988;93(5):941-945.
23. Maibach HI. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermat. 1987;16(1):1-8.
24. Confino-Cohen R, Goldberg A. Successful desensitization of methylphenidate-induced rash. J Child Adolesc Psychopharmacol. 2005;15(4):703-705.
25. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107(6):e105-e119.
26. Quinn D, Wigal S, Swanson J, et al. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43(11):1422-1429.
27. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112(5):e404-e413.
28. Swanson JM, Wigal SB, Wigal T, et al; COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics. 2004;113(3 pt 1):e206-e216.
29. Wolraich ML, Greenhill LL, Pelham W, et al; Concerta Study Group. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883-892.